Inhibikase Therapeutics elects Steven Gilman to board
This article was originally published in Scrip
Executive Summary
Inhibikase Therapeutics, a creator of anti-infective therapies, has elected Dr Steven Gilman to its board of directors. Dr Gilman currently serves as executive vice-president, R&D and chief scientific officer at Cubist Pharmaceuticals. Prior to this, he was chairman, president and CEO of ActivBiotics.